DROPLET-BASED SELECTION

• US 20090068170A1
• Filed: 07/11/2008
• Published: 03/12/2009
• Est. Priority Date: 07/13/2007
• Status: Abandoned Application

• Current Assignee: President and Fellows of Harvard College (Harvard Corporation), The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Inventors: Koester, Sarah, Merten, Christoph, Mootha, Vamsi K., Duan, Honey, Gilbert, John R., Griffiths, Andrew, Weitz, David A., Agresti, Jeremy, Heyman, John
• Application Number:
  US12/172,186
• Publication Number:
  US 20090068170A1
• Time in Patent Office: Days
• US Class Current: 424/130.100
• CPC Class Codes: B01F 33/3021 the components to be mixed being combined in a single independent droplet, e.g. these droplets being divided by a non-miscible fluid or consisting of independent droplets
• CPC Class Codes: B01F 33/3031 using electro-hydrodynamic [EHD] or electro-kinetic [EKI] phenomena to mix or move the fluids
• CPC Class Codes: B01L 3/502784 specially adapted for droplet or plug flow, e.g. digital microfluidics automatic analysis using a stream of discrete samples in a tube system G01N35/08
• CPC Class Codes: G01N 15/1459 the analysis being performed on a sample stream
• CPC Class Codes: G01N 15/149 specially adapted for sorting particles, e.g. by their size or optical properties
• CPC Class Codes: G01N 33/505 involving T-cells
• CPC Class Codes: G01N 33/5052 involving B-cells
• CPC Class Codes: G01N 33/5436 with ligand physically entrapped within the solid phase liposomes G01N33/5432; immunological test elements G01N33/54386
• CPC Class Codes: G01N 33/6854 Immunoglobulins

Abstract

The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is screened to determine proteins, antibodies, polypeptides, peptides, nucleic acids, or the like. For example, cells able to secrete species such as antibodies may be selected according to certain embodiments of the invention. Examples of such cells include, for instance, immortal cells such as hybridomas, or non-immortal cells such as B-cells. For instance, blood cells may be encapsulated within a plurality of fluidic droplets, and the cells able to produce antibodies may be determined. In some cases, expression or secretion levels may be determined using signaling entities, for example, determinable microparticles present within the fluidic droplet. Other aspects of the invention relate to kits involving such fluidic droplets, methods of promoting the making or use of such fluidic droplets, and the like.

Claims

1-103. -103. (canceled)

104. A method, comprising:

providing a plurality of fluidic droplets contained within a liquid, wherein at least some of the fluidic droplets contain non-immortal cells; and

determining a characteristic of a species secreted by the non-immortal cells within the fluidic droplets.

108. The method of claim 104, wherein the characteristic of the species is determined by exposing the non-immortal cell to a second cell.

112. The method of claim 104, wherein the characteristic of the species is determined by exposing the non-immortal cell to a first target and a second target.

113. The method of claim 112, wherein the first target is a cell and the second target is a cell.

114. The method of claim 112, wherein the first target is a protein and the second target is a protein.

105-107. -107. (canceled)

109-111. -111. (canceled)

115-136. -136. (canceled)

137. A method, comprising:

providing a fluidic droplet contained within a liquid, the droplet containing an antibody-producing cell and a target;

culturing the antibody-producing cell to secrete antibodies able to recognize the target; and

determining association of the antibodies to the target.

138. The method of claim 137, wherein the antibody comprises a first signaling entity and the target cell comprises a second signaling entity.

139. The method of claim 138, comprising determining association of the first signaling entity and the second signaling entity.

140. The method of claim 137, wherein the target is a protein.

141. The method of claim 137, wherein the target is a cell.

143. The method of claim 137, comprising providing a plurality of fluidic droplets, including a first droplet containing a first target able to produce a first antibody and a second droplet containing a second target able to produce a second antibody distinguishable from the first antibody.

142. (canceled)

144-172. -172. (canceled)

173. A method, comprising:

removing blood cells from a subject;

encapsulating at least some of the blood cells in a plurality of fluidic droplets; and

at least partially separating, from the plurality of fluidic droplets, droplets containing antibody-producing cells.

177. The method of claim 173, wherein the blood cells are encapsulated in the plurality of fluidic droplets at an average ratio of no more than about 1 blood cell/fluidic droplet.

178. The method of claim 173, further comprising determining a characteristic of the antibodies produced by the blood cells.

179. The method of claim 178, wherein determining a characteristic of the antibodies comprises exposing the antibodies to a signaling entity comprising a microparticle and an agent, immobilized relative to the microparticle, able to bind the species.

181. The method of claim 173, further comprising cloning DNA from the antibody-producing cells.

182. The method of claim 181, wherein the DNA is amplified prior to cloning.

213. The method of claim 173, further comprising:

sequencing DNA from at least one of the antibody-producing cells; and

inserting at least a portion of the DNA in a host cell.

174-176. -176. (canceled)

180. (canceled)

183. (canceled)

184. The method of claim 183, further comprising culturing the host cell to express the DNA as a protein.

186. The method of claim 184, further comprising administering the protein to the subject.

185. (canceled)

187-212. -212. (canceled)

214-225. -225. (canceled)